Dergiler / Turkish Journal of Internal Medicine / 2022 / Cilt: 4 - Sayı: 3

Time Elapsed For Switching From Oral Antidiabetic Therapy to Insulin Therapy in Type 2 Diabetic Patients and Evaluation of The Factors Affecting This Period

Sayfa
106–111
Yayın Tarihi
2022-07-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion The body mass index level, presence of hypertension, education level and age at the onset of diabetes were the significant factors affecting the time elapsed for switching to insulin therapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background We aimed to determine the time elapsed for switching from oral antidiabetic therapy to insulin therapy in patients with type 2 diabetes mellitus and the factors that affect this period.
📊
Temel Bulgular & Veri:Material and Methods Three hundred fifteen patients with type 2 diabetes mellitus who were followed up in the diabetes outpatient clinic were included in the study.
💡
Sonuç & Katkı:Conclusion The body mass index level, presence of hypertension, education level and age at the onset of diabetes were the significant factors affecting the time elapsed for switching to insulin therapy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Type 2 Diabetes Mellitus · Oral antidiabetics · Insulin therapy

Abstract

Background We aimed to determine the time elapsed for switching from oral antidiabetic therapy to insulin therapy in patients with type 2 diabetes mellitus and the factors that affect this period. Material and Methods Three hundred fifteen patients with type 2 diabetes mellitus who were followed up in the diabetes outpatient clinic were included in the study. The gender, education level, age of onset of diabetes, presence of hypertension, smoking and body mass index of the patients were examined, and the effects of these variables on time elapsed for switching to insulin therapy were analyzed in three phases. Results Three hundred fifteen patients (117 males, 198 females) were enrolled in the study. The mean time elapsed for switching from oral antidiabetic therapy to insulin therapy was 9.93±6.67 years. The effects of education level, age at the onset of diabetes, presence of hypertension, and body mass index on time elapsed for switching to insulin therapy were found to be statistically significant (p0.05). The time elapsed for switching to insulin therapy shortened as the education level, the age at the onset of diabetes, and body mass index level increased. It was found that hypertension in patients with type 2 diabetes mellitus prolongs the time elapsed for switching to insulin therapy. Conclusion The body mass index level, presence of hypertension, education level and age at the onset of diabetes were the significant factors affecting the time elapsed for switching to insulin therapy.

🔖

Bu Makaleye Atıf Yap

ARSLAN, K., BOYOGLU, A., TEMİZEL, M. (2022). Time Elapsed For Switching From Oral Antidiabetic Therapy to Insulin Therapy in Type 2 Diabetic Patients and Evaluation of The Factors Affecting This Period. Turkish Journal of Internal Medicine, Cilt: 4 - Sayı: 3, 106–111. https://ajindex.com/articles/808959

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R
  2. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov
  3. 107843. doi: 10.1016/j.diabres.2019.107843. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013
  4. 36 Suppl 1(Suppl 1):S67-S74. doi:10.2337/dc13-S067. Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015
  5. 6(1):109-24. doi:10.4239/wjd.v6.i1.109. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi E. Natural history of β-cell adaptation and failure in type 2 diabetes. Mol Aspects Med. 2015
  6. doi:10.1016/j.mam.2014.12.002. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
  7. American Diabetes Association
  8. European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan
  9. 32(1):193-203. doi: 10.2337/dc08-9025. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016
  10. doi:10.4137/BMI.S38440. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes. 1997 Sep
  11. 46 Suppl 2:S101-3. doi: 10.2337/diab.46.2.s101. Sreenan S. HbA1c levels exceed recommended targets prior to initiation or intensification of insulin therapy in clinical practice: baseline data from the PREDICTIVE™ European cohort. EASD 2006, Abstract 0897. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L
  12. International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005 Nov
  13. 28(11):2673-9. doi: 10.2337/diacare.28.11.2673. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B
  14. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Compl